Meeting
2023 ASCO Annual Meeting
Treatment at twilight: Is less more in the management of octogenarians with non-small cell lung cancer (NSCLC)?
Authors
Ethan Burns
Houston Methodist Cancer Center, Houston, TX
Ethan Burns , Sunil Mathur , Ryan Blair Kieser , Wan Hsiang Chen , Eric Bernicker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9042)
DOI
10.1200/JCO.2023.41.16_suppl.9042
Abstract #
9042
Poster Bd #
30
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Combined pulsed radiotherapy (QUAD shot regimen) with immune checkpoint inhibition (ICI) to enhance immune response for LAHNSCC in patients considered ineligible for curative intent therapy.
First Author: Jennifer F. De Los Santos
Poster
2022 ASCO Annual Meeting
Real-world effectiveness of immune checkpoint inhibitors alone or in combination with chemotherapy in metastatic non–small cell lung cancer.
First Author: Lingzhi Hong
Poster
2021 ASCO Annual Meeting
The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study.
First Author: Karen Kelly
Poster
2021 ASCO Annual Meeting
Optimal next-generation sequencing (NGS) panel for estimating tumor mutation burden (TMB) and its clinical implication for non-small cell lung cancer (NSCLC).
First Author: Takaya Ikeda